Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 4,900
- Avg volume
- 18,928
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 1%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maint...
Show more
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 61 4 1229 2977
- Website
- https://www.nextscience.com
- Address
- Australia Square, Level 14 264-278 George Street, Sydney, Australia
Latest news
No headlines yet.
